CSTL
Castle Biosciences, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$32.91
+0.80%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 357.3M | 344.2M | 332.1M | 219.8M | 137.0M |
| Cost of Revenue | 81.3M | 71.0M | 60.2M | 45.0M | 32.0M |
| Gross Profit | 276.0M | 273.2M | 271.9M | 174.8M | 105.0M |
| Operating Expenses | |||||
| R&D Expense | 55.4M | 51.9M | 52.0M | 53.6M | 44.9M |
| SG&A Expense | 243.7M | 229.3M | 200.0M | 180.2M | 143.0M |
| General & Admin Expense | 95.5M | 91.2M | 76.6M | 66.5M | 56.4M |
| Selling & Marketing Expense | 148.1M | 138.1M | 123.5M | 113.7M | 86.6M |
| Other Expenses | 9.0M | 34.8M | 11.1M | 9.0M | (10.0M) |
| Total Operating Expenses | 308.1M | 316.0M | 263.2M | 242.8M | 177.9M |
| Cost and Expenses | 389.4M | 387.0M | 323.4M | 287.8M | 209.9M |
| Operating Income (EBIT) | (32.1M) | (42.8M) | 8.7M | (68.0M) | (72.9M) |
| Non-Operating | |||||
| Interest Income | 10.6M | 11.8M | 12.9M | 10.6M | 4.0M |
| Interest Expense | 375.0K | 86.0K | 577.0K | 11.0K | 17.0K |
| Net Interest Income | 10.3M | 11.7M | 12.3M | 10.6M | 4.0M |
| Other Non-Op Income/Expense | 12.9M | 13.3M | 12.9M | 10.6M | 4.0M |
| Non-Operating Income (excl Interest) | (13.3M) | (13.4M) | (13.5M) | (10.6M) | (4.0M) |
| EBT (Pre-Tax Income) | (19.2M) | (29.5M) | 21.6M | (57.4M) | (68.9M) |
| Income Tax Expense | 212.0K | (5.4M) | 3.3M | 101.0K | (1.8M) |
| Bottom Line | |||||
| Net Income | (19.4M) | (24.2M) | 18.2M | (57.5M) | (67.1M) |
| Earnings from Cont. Ops | (19.4M) | (24.2M) | 18.2M | (57.5M) | (67.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (19.4M) | (24.2M) | 18.2M | (57.5M) | (67.1M) |
| Per Share | |||||
| Basic EPS | ($0.66) | ($0.83) | $0.66 | ($2.14) | ($2.58) |
| Diluted EPS | ($0.66) | ($0.83) | $0.62 | ($2.14) | ($2.58) |
| Revenue Per Share | $11.75 | $11.88 | $11.96 | $8.20 | $5.26 |
| Shares | |||||
| Basic Shares Outstanding | 30.4M | 29.0M | 27.8M | 26.8M | 26.1M |
| Diluted Shares Outstanding | 30.4M | 29.0M | 29.3M | 26.8M | 26.1M |
| Profitability Metrics | |||||
| EBITDA | (3.2M) | 11.3M | 38.1M | (45.0M) | (58.3M) |
| D&A | 15.6M | 40.8M | 16.0M | 12.3M | 10.5M |
| EBIT | (18.8M) | (29.4M) | 22.1M | (57.4M) | (68.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026